2-Tetradecyl-quinoline | 353743-88-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-Tetradecyl-quinoline
• 英文别名: 2-Tetradecylquinoline
• CAS: 353743-88-1
• 化学式: C₂₃H₃₅N
• 分子量: 325.538
• InChiKey: YWOSVGKMVIXHQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  24
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  喹啉-N-氧化物 以 四氢呋喃 为溶剂， 生成 2-Tetradecyl-quinoline
  参考文献：
  名称：

  快速制备2-取代的喹啉

  摘要：

  由格氏试剂和喹啉盐的混合物在溶液中合成了2-取代的喹啉文库。格利雅试剂在一个锅中制备，利用了从非反应性烷基卤化物制备的夹带方法。然后2-烷基喹啉的混合物易于进行生物学测试，或在进行生物学筛选之前通过离心分配色谱法（CPC）进行分离。

  DOI：

  10.1016/s0040-4039(01)00604-9

文献信息

• Expeditious preparation of 2-substituted quinolines
  作者：Mohamed A Fakhfakh、Xavier Franck、Alain Fournet、Reynald Hocquemiller、Bruno Figadère

  DOI：10.1016/s0040-4039(01)00604-9

  日期：2001.6

  A library of 2-substituted quinolines was synthesized in solution from mixtures of Grignard reagents and a quinolinium salt. Grignard reagents were prepared in one pot, taking advantage of the entrainment method for their preparation from unreactive alkyl halides. Then mixtures of 2-alkylquinolines were readily accessible for biological tests or separated by centrifugal-partition chromatography (CPC)

  由格氏试剂和喹啉盐的混合物在溶液中合成了2-取代的喹啉文库。格利雅试剂在一个锅中制备，利用了从非反应性烷基卤化物制备的夹带方法。然后2-烷基喹啉的混合物易于进行生物学测试，或在进行生物学筛选之前通过离心分配色谱法（CPC）进行分离。
• Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections
  作者：Mohammed A. Fakhfakh、Alain Fournet、Eric Prina、Jean-François Mouscadet、Xavier Franck、Reynald Hocquemiller、Bruno Figadère

  DOI：10.1016/j.bmc.2003.09.007

  日期：2003.11

  We report the synthesis of substituted quinolines and their in vitro biological evaluation against the causal agents of cutaneous leishmaniasis, visceral leishmaniasis, African trypanosomiasis and Chagas' disease. Furthermore, several quinolines have also been tested for their anti-retroviral activity in HIV-1 infected cells. The structure activity relationships of these new synthetic compounds are discussed and emphasis was placed on the treatment of leishmania/HIV co-infections. (C) 2003 Elsevier Ltd. All rights reserved.